Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ: IMVT ) with a Buy and raises the price target from $57 to $61.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.